The End of "Benign": Drivers of the ICD-O Code Upgrade for Pituitary Neuroendocrine Tumors and the Molecular...

The International Classification of Diseases for Oncology (ICD-O) behavior code for pituitary neuroendocrine tumors (PitNETs) underwent a historic shift from "/0" (benign) to "/3" (primary malignant) in the 2022 fifth edition of the WHO classification. This coding change is not a mere terminological substitution but represents a profound reconceptualization of the biological nature of PitNETs-transitioning from the classical paradigm of "indolent benign adenoma" to a novel framework of "full-spectrum neuroendocrine tumors with malignant potential." This article systematically reviews the historical context and driving forces behind the evolution of the ICD-O code from /0 to /3. It then elaborates on the molecular advances underpinning this coding change across three levels: genetic mutations, epigenetic remodeling, and post-transcriptional regulation. Crucially, it emphasizes that the clinically validated morphologic subtyping, which has proven prognostic value, often but not always correlates with these molecular alterations, and remains the cornerstone of patient management. Finally, it discusses unresolved issues in the current classification system and future directions. In conclusion, the transition of the ICD-O code from /0 to /3 marks a critical milestone in PitNET taxonomy, signifying its shift from a "histological" paradigm, where molecular insights complement, but do not replace, a precise morphologic classification.